SCDM: Society of Clinical Data Management Annual Conference

Join us in the Pacific Northwest and network with your fellow biopharma and device development professionals to help move the Clinical Data Management discipline forward. Visit our booth #308 to learn our own CDM experts' contributions to the 2018 agenda.

American Conference on Pharmacometrics (ACoP9)

We're looking forward to heading to San Diego to network with our clinical research colleagues at ACoP9. Visit us at booth #11 and learn how our innovative QPP approaches are helping medicine and device developers to gain the key insights necessary to improve their clinical research decision-making.

DACH 2018: Outsourcing Clinical Trials

Cytel sponsors this timely event designed for clinical research professionals in the German-speaking countries.  Through in-depth research conducted with the regions' biopharma companies, this event will deliver insight, debate and discussion on high priority outsourcing, operations and technology-based themes in the clinical trial space.

PhUSE Annual Connect EU 2018

This year in Frankfurt, PhUSE EU Connect is again Europe's largest congregation of biopharma statistical programmers. 2018 meeting themes include how our work can improve through insights into machine learning solutions, insight-enabling visualisations and interactive displays. Visit booth #6 to learn Cytel's own 2018 agenda contributions.

Outsourcing in Clinical Trials: New England 2018

Cytel is again a supporting sponsor of the Outsourcing Clinical Trials conference in Boston.  Join us there for a conversation towards developing the practical strategies to help your company, whether big or small, to improve developmental timelines.

EUGM 2018: East Symposium & User Group Meeting

Since 2011, the East Symposium and User Group Meeting has brought together industry experts and thought leaders to discuss the future of innovative clinical trials. This annual meeting guides the development of East, the industry's leading clinical trial design software. New for 2018 will also be a discussion on applications of Data Science to drug development.
We're proud to announce our scientific committee includes Armin Schueler from host Merck KgA, Tobias Muetze of Novartis with Sanofi's Gautier Paux. The 2018 programme will be posted soon.

Clinical Operations in Oncology Trials (EU)

2018 Clinical Operations in Oncology Trials EU attendees can debate the practical strategies to help their company improve operational efficiencies in conducting oncology clinical research. Cytel adaptive trial and data science experts will again contribute. Learn about this year's presentation at our booth and how innovative approaches trial designs can increase your trial's chances for success.

Partnerships in Clinical Trials EU

Partnerships in Clinical Trials (PCT) Congress brings together trial stakeholders searching to improve clinical research. 2018 session streams include: "Disruptive Innovation, Technology and Big Dataset Access" and "How Small to Mid-Size Pharma and Biotech can Outsource to Find the Ideal Partner". Stop by the Cytel booth to learn how we're helping drug development sponsors to conduct better trials.

14th Annual Scrip Awards

The 2018 Scrip Awards categories range from rewarding the broader achievements of drug development leaders to innovations in deal-making, advances in R&D and the more personal accomplishments of teams and individuals.

BioData World Congress 2018

Cytel will again sponsor this important gathering of Life Science professionals and share how our Data Science experts are helping biopharma companies to formulate optimal program development strategies. In 2017, Cytel's Rajat Mukherjee spoke in the track "Transforming Big Data into Smart Data".

SCOPE Annual Summit

Cytel experts will reveal new tools and techniques at the largest gathering of clinical study professionals in North America.  Our own Charles Liu will speak on the use of simulations to predict recruitment in  "Accurate patient enrollment forecasting using Enforesys: Case studies and lessons learned".

Stop by our booth #207 to learn how a biometrics focus can improve your own program's chance of clinical success.

ASCPT Annual Meeting

Cytel Pharmacometric team-members will again contribute to the 2019 meeting agenda.  Stop by the Cytel booth #46 to learn their 2019 schedule and to discuss how you could gain even greater insights from your data.

EUGM 2017 Presentations

The 5th annual East User Group Meeting (EUGM) in Cambridge, MA, featuring expert contributions from hosts Biogen, AstraZeneca, Pfizer as well as Cytel. Their presentation topics included designing basket trials, new methods for optimizing the distribution of sites and utilizing safety statistics in adverse event monitoring.

2017 ASA Biopharma Regulatory Industry Statistics Workshop

See Cytel expert presentation slidesets:

• Sample Size Re-Estimation: Controlling Type-1 Error, by Yannis Jemiai 
• Bayesian Study Design to Leverage Informative Prior Information, by Jim Bolognese and Sam Hsiao
• Efficiency Promising of Zone Designs, by Cyrus Mehta, Sam Hsiao & Lingyun Liu
• PS4b Parallel Session, by Caroline Morgan

Innovative Trial Design Symposium: Adaptive Designs and Improving Operational Efficiency

Hear Jim Bolognese and Narinder Nangia from Alkermes on designing Phase 2 trials based on program-level optimization (i.e., optimizing the entire Phase 2/3 drug development strategy). You'll learn how:

• Phase 2 sample size can be optimized to yield maximum eNPV when selecting 1 or 2 doses for Phase 3
• Studying more doses in Phase 2 can improve Probability of Success, yielding higher product eNPV, unless AE rates low for all doses

Symposium: Development in Oncology and Orphan Indications

Download the slidesets and watch the presentation replays from the Cytel and Pfizer open seminar and applied trial design workshop focused on oncology and rare disease clinical development.  In addition to biostatisticians, clinicians and R&D leadership as well will find the expert talks and trial design workshop enlightening.

Watch Demo: Dual-Agent Phase 1 Trials with East^®

East^® Escalate version 6.4 adds two dose escalation design methods to support single- and dual-agent studies:
(1) BLRM method extension for dual-combination trials
(2) Product of Independent beta Probabilities Escalation (PIPE).  Demonstration highlights:
- Simulate and compare designs under different dose-toxicity profile assumptions
- Determining best dose for next patient cohort based on modeling the accumulating data
- Communicating effectively with clinicians to guide dosing decisions, increase success rates

Watch: Asking the Right Questions of Your Data: Experiences with Model-informed Development

Cytel experts reveal how QPP (Quantitative Pharmacology and Pharmacometrics) -based insights can guide the determination of the optimal program development strategy. Presented by Cecilia Fosser, Director, Quantitative Pharmacology & Pharmacometrics and Chuck Gelb, Sr. Business Development Director.

Watch: Trial Innovation and Implementation with East^® Training

In March 2016, biostatistical and drug development operations innovators met to help bridge the gap between newer methods and the medical, operational and regulatory realities.

Watch: Know the Risks You Need to Manage in Clinical Outsourcing

Time and again, we hear “Outsourcing key clinical functions is a clinical development risk mitigation strategy”. But do you really know the risks you need to mitigate in today's clinical research? Little wonder why the results so often disappoint: Sponsors don't know well what they should be considering to succeed.

Watch: Innovative Design and Optimal Trial Decision-Making

The Cytel and Sanofi trial design symposium presented ways to implement innovative approaches to dose finding and dose escalation trials, ultimately to better support confirmatory efforts. Hear expert presentations from trial and decision experts at AstraZeneca, Sanofi, Takeda and Cytel.

Placeholder Title

Solving Difficult Research Problems Using StatXact, hosted by Chris Corcoran

Adaptive trials can bring clarity and optionality to R&D decision-making, but historically it’s been difficult for clinical and finance professionals to "speak the same language" about the relationship between trial strategy and value.